298 related articles for article (PubMed ID: 33785524)
1. The AXL-PYK2-PKCα axis as a nexus of stemness circuits in TNBC.
Khera L; Vinik Y; Maina F; Lev S
Life Sci Alliance; 2021 Jun; 4(6):. PubMed ID: 33785524
[TBL] [Abstract][Full Text] [Related]
2. Protein kinase C α is involved in the regulation of AXL receptor tyrosine kinase expression in triple-negative breast cancer cells.
Yue CH; Liu LC; Kao ES; Lin H; Hsu LS; Hsu CW; Lin YY; Lin YS; Liu JY; Lee CJ
Mol Med Rep; 2016 Aug; 14(2):1636-42. PubMed ID: 27357025
[TBL] [Abstract][Full Text] [Related]
3. Combined inhibition of AXL, Lyn and p130Cas kinases block migration of triple negative breast cancer cells.
Pénzes K; Baumann C; Szabadkai I; Orfi L; Kéri G; Ullrich A; Torka R
Cancer Biol Ther; 2014; 15(11):1571-82. PubMed ID: 25482942
[TBL] [Abstract][Full Text] [Related]
4. PYK2 negatively regulates the Hippo pathway in TNBC by stabilizing TAZ protein.
Kedan A; Verma N; Saroha A; Shreberk-Shaked M; Müller AK; Nair NU; Lev S
Cell Death Dis; 2018 Sep; 9(10):985. PubMed ID: 30250159
[TBL] [Abstract][Full Text] [Related]
5. Targeting of PYK2 Synergizes with EGFR Antagonists in Basal-like TNBC and Circumvents HER3-Associated Resistance via the NEDD4-NDRG1 Axis.
Verma N; Müller AK; Kothari C; Panayotopoulou E; Kedan A; Selitrennik M; Mills GB; Nguyen LK; Shin S; Karn T; Holtrich U; Lev S
Cancer Res; 2017 Jan; 77(1):86-99. PubMed ID: 27793840
[TBL] [Abstract][Full Text] [Related]
6. The TRAIL receptor agonist drozitumab targets basal B triple-negative breast cancer cells that express vimentin and Axl.
Dine JL; O'Sullivan CC; Voeller D; Greer YE; Chavez KJ; Conway CM; Sinclair S; Stone B; Amiri-Kordestani L; Merchant AS; Hewitt SM; Steinberg SM; Swain SM; Lipkowitz S
Breast Cancer Res Treat; 2016 Jan; 155(2):235-51. PubMed ID: 26759246
[TBL] [Abstract][Full Text] [Related]
7. MicroRNA-200b targets protein kinase Cα and suppresses triple-negative breast cancer metastasis.
Humphries B; Wang Z; Oom AL; Fisher T; Tan D; Cui Y; Jiang Y; Yang C
Carcinogenesis; 2014 Oct; 35(10):2254-63. PubMed ID: 24925028
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of the novel tyrosine kinase inhibitor DCC-2036 on triple-negative breast cancer stem cells through AXL-KLF5 positive feedback loop.
Shen Y; Zhu Q; Xiao M; Yin L; Feng W; Feng J; He J; Li P; Chen X; Ding W; Zhong J; Zeng Z; Xie Z; Liu J; Zu X
Cell Death Dis; 2022 Aug; 13(8):749. PubMed ID: 36042208
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic Activity of Anti-AXL Antibody against Triple-Negative Breast Cancer Patient-Derived Xenografts and Metastasis.
Leconet W; Chentouf M; du Manoir S; Chevalier C; Sirvent A; Aït-Arsa I; Busson M; Jarlier M; Radosevic-Robin N; Theillet C; Chalbos D; Pasquet JM; Pèlegrin A; Larbouret C; Robert B
Clin Cancer Res; 2017 Jun; 23(11):2806-2816. PubMed ID: 27923843
[No Abstract] [Full Text] [Related]
10. Global phosphotyrosine survey in triple-negative breast cancer reveals activation of multiple tyrosine kinase signaling pathways.
Wu X; Zahari MS; Ma B; Liu R; Renuse S; Sahasrabuddhe NA; Chen L; Chaerkady R; Kim MS; Zhong J; Jelinek C; Barbhuiya MA; Leal-Rojas P; Yang Y; Kashyap MK; Marimuthu A; Ling M; Fackler MJ; Merino V; Zhang Z; Zahnow CA; Gabrielson E; Stearns V; Roa JC; Sukumar S; Gill PS; Pandey A
Oncotarget; 2015 Oct; 6(30):29143-60. PubMed ID: 26356563
[TBL] [Abstract][Full Text] [Related]
11. The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells.
Meyer AS; Miller MA; Gertler FB; Lauffenburger DA
Sci Signal; 2013 Aug; 6(287):ra66. PubMed ID: 23921085
[TBL] [Abstract][Full Text] [Related]
12. BCL6 and the Notch pathway: a signaling axis leading to a novel druggable biotarget in triple negative breast cancer.
De Santis F; Romero-Cordoba SL; Castagnoli L; Volpari T; Faraci S; Fucà G; Tagliabue E; De Braud F; Pupa SM; Di Nicola M
Cell Oncol (Dordr); 2022 Apr; 45(2):257-274. PubMed ID: 35357654
[TBL] [Abstract][Full Text] [Related]
13. Accelerating AXL targeting for TNBC therapy.
Khera L; Lev S
Int J Biochem Cell Biol; 2021 Oct; 139():106057. PubMed ID: 34403827
[TBL] [Abstract][Full Text] [Related]
14. Stat3/Oct-4/c-Myc signal circuit for regulating stemness-mediated doxorubicin resistance of triple-negative breast cancer cells and inhibitory effects of WP1066.
Cheng CC; Shi LH; Wang XJ; Wang SX; Wan XQ; Liu SR; Wang YF; Lu Z; Wang LH; Ding Y
Int J Oncol; 2018 Jul; 53(1):339-348. PubMed ID: 29750424
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic Landscape of AXL Receptor Kinase in Triple-Negative Breast Cancer.
Ozyurt R; Ozpolat B
Mol Cancer Ther; 2023 Jul; 22(7):818-832. PubMed ID: 37028809
[TBL] [Abstract][Full Text] [Related]
16. n-Butylidenephthalide Regulated Tumor Stem Cell Genes EZH2/AXL and Reduced Its Migration and Invasion in Glioblastoma.
Yen SY; Chuang HM; Huang MH; Lin SZ; Chiou TW; Harn HJ
Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28208648
[TBL] [Abstract][Full Text] [Related]
17. STAT3 activation by leptin receptor is essential for TNBC stem cell maintenance.
Thiagarajan PS; Zheng Q; Bhagrath M; Mulkearns-Hubert EE; Myers MG; Lathia JD; Reizes O
Endocr Relat Cancer; 2017 Aug; 24(8):415-426. PubMed ID: 28729467
[TBL] [Abstract][Full Text] [Related]
18. Systems modelling of the EGFR-PYK2-c-Met interaction network predicts and prioritizes synergistic drug combinations for triple-negative breast cancer.
Shin SY; Müller AK; Verma N; Lev S; Nguyen LK
PLoS Comput Biol; 2018 Jun; 14(6):e1006192. PubMed ID: 29920512
[TBL] [Abstract][Full Text] [Related]
19. BTF3 promotes stemness and inhibits TypeⅠInterferon signaling pathway in triple-negative breast cancer.
Wang H; Gao L; Qi M; Su P; Xiong X; Zhao J; Hu J; Han B
Biochem Biophys Res Commun; 2021 Jan; 537():22-28. PubMed ID: 33383560
[TBL] [Abstract][Full Text] [Related]
20. AXL Controls Directed Migration of Mesenchymal Triple-Negative Breast Cancer Cells.
Zajac O; Leclere R; Nicolas A; Meseure D; Marchiò C; Vincent-Salomon A; Roman-Roman S; Schoumacher M; Dubois T
Cells; 2020 Jan; 9(1):. PubMed ID: 31963783
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]